Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms

American Journal of Hematology

Volumn 87, Issue 2, 2012, Pages 175-182

  Anderson, Lesley A ^a   Duncombe, Andrew S ^b   Hughes, Maria ^a   Mills, Moyra E ^a   Wilson, Jessica C ^a   McMullin, Mary F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON; BENZENE; FERTILIZER; PAINT; PESTICIDE; PETROLEUM;

ALCOHOL CONSUMPTION; ARTICLE; AUTOIMMUNE DISEASE; BLOOD DONOR; BONE MARROW CANCER; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CROHN DISEASE; DEMOGRAPHY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ETHNICITY; FAMILY HISTORY; FOLLOW UP; HUMAN; LIFESTYLE; MYELOPROLIFERATIVE DISORDER; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK FACTOR; SMOKING; THROMBOCYTHEMIA;

AUTOIMMUNITY; BLOOD DONORS; ENVIRONMENTAL POLLUTANTS; ETHNIC GROUPS; FEMALE; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; LIFE STYLE; MALE; MUTATION; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS;

EID: 84855937328     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22212     Document Type: Article

References (56)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
2. Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: Essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 2001; 49: 164-166.
3. Kutti J. Platelet production rate in polycythemia vera after myelosuppressive therapy. Acta Med Scand 1972; 192: 161-164.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
5. Bojesen SE, Nielson C, Birgens H, et al. JAK2 V617F mutation positives in the general population. J Clin Oncol 2010; 28: 6599.
6. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
7. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 2006; 108: 3472-3476.
8. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182-6192.
9. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
10. Pardanani A, Lasho T, Finke C, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010; 24: 1713-1718.
11. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
12. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41: 446-449.
13. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41: 455-459.
14. Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007; 25: 5630-5635.
15. Zoloth SR, Michaels DM, Villalbi JR, Lacher M. Patterns of mortality among commercial pressmen. J Natl Cancer Inst 1986; 76: 1047-1051.
16. Kaplan SD. Update of a mortality study of workers in petroleum refineries. J Occup Med 1986; 28: 514-516.
17. Merk K, Mattsson B, Mattsson A, et al. The incidence of cancer among blood donors. Int J Epidemiol 1990; 19: 505-509.
18. Hayes RB, Blair A, Stewart PA, et al. Mortality of U.S. embalmers and funeral directors. Am J Ind Med 1990; 18: 641-652.
19. Pizzolito S, Barbone F, Rizzi C, et al. Parathyroid adenomas and malignant neoplasms: coincidence or etiological association? Adv Clin Path 1997; 1: 275-280.
20. Johnson ES, Zhou Y, Lillian Yau C, et al. Mortality from malignant diseases-update of the Baltimore union poultry cohort. Cancer Causes Control 2010; 21: 215-221.
21. Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 1992; 7: 251-255.
22. Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: A study of 842 cases. Hematol Cell Ther 1998; 40: 159-165.
23. Hemminki K, Jiang Y. Familial polycythemia vera: Results from the Swedish Family-Cancer Database [7]. Leukemia 2001; 15: 1313-1315.
24. Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24, 577 first-degree relatives of 11, 039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112: 2199-2204.
25. Quiroga Micheo E, Calcagno EJ, Calabria SI, et al. Retrospective epidemiological study of hemopoietic system neoplasms in Argentina. Medicina 1981; 41: 187-200.
26. Giles GG, Lickiss JN, Baikie MJ. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: Occupational and familial aspects. J Natl Cancer Inst 1984; 72: 1233-1240.
27. Lickiss JN, Giles GG, Baikie MJ, et al. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: Patterns in space and time. J Natl Cancer Inst 1984; 72: 1223-1231.
28. Pasqualetti P, Casale R, Colantonio D, Collacciani A. Occupational risk for hematological malignancies. Am J Hematol 1991; 38: 147-149.
29. Terreros MC, Apezteguia M, Slavutsky IR, Guimarey LM. Exposure to occupational and environmental risk factors in hematologic disorders. Neoplasia 1997; 14: 133-136.
30. Mele A, Visani G, Pulsoni A, et al. Risk factors for essential thrombocythemia-A case-control study. Cancer 1996; 77: 2157-2161.
31. Falcetta R, Sacerdote C, Bazzan M, et al. Occupational and lifestyle risk factors for essential thrombocytemia: A case-control study. G Ital Med Lav Ergon 2003; 25: 9-12.
32. Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009; 100: 822-828.
33. Kristinsson SY, Landgren O, Samuelsson J, et al. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010; 95: 1216-1220
34. Manoharan A, Garson OM. Familial polycythaemia vera: A study of 3 sisters. Scand J Haematol 1976; 17: 10-16.
35. Ratnoff WD, Gress RE. The familial occurrence of polycythemia vera: Report of a father and son, with consideration of the possible etiologic role of exposure to organic solvents, including tetrachloroethylene. Blood 1980; 56: 233-236.
36. Nielsen H, Nordin H. Polycythemia vera in a Danish family. Ugeskr Laeger 1991; 153: 2072-2073.
37. Inaba T, Shimazaki C, Hirai H, et al. Familial polycythemia vera in father and daughter. Am J Hematol 1996; 51: 172.
38. Schlemper RJ, Vandermaas APC, Eikenboom JCJ. Familial essential thrombocythemia-Clinical characteristics of 11 cases in one family. Ann Hematol 1994; 68: 153-158.
39. Eyster ME, Saletan SL, Rabellino EM, et al. Familial essential thrombocythemia. Am J Med 1986; 80: 497-502.
40. Wiestner A, Padosch SA, Ghilardi N, et al. Hereditary thrombocythaemia is a genetically heterogeneous disorder: Exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol 2000; 110: 104-109.
41. Yagisawa M, Kamizaki K, Nagase T, et al. Familial essential thrombocythemia in a daughter and mother. Nippon Naika Gakkai Zasshi 1990; 79: 531-532.
42. Pardanani A, Fridley BL, Lasho TL, et al. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008; 111: 2785-2789.
43. Ferguson LR, Han DY, Fraser AG, et al. Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res 2010; 690: 108-115.
44. Espinosa G, Font J, Munoz-Rodriguez FJ, et al. Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: A coincidental coexistence or a causal relationship? Clin Rheumatol 2002; 21: 309-313.
45. Montalto M, Biolato M, Gallo A, et al. Severe giant cell arteritis associated with essential thrombocythaemia. Int J Immunopathol Pharmacol 2010; 23: 1271-1274.
46. Tondel M, Persson B, Carstensen J. Myelofibrosis and benzene exposure. Occup Med (Lond) 1995; 45: 51-52.
47. Wolff SP. Correlation between car ownership and leukemia: is non-occupational exposure to benzene from petrol and motor vehicle exhaust a causative factor in leukemia and lymphoma? Experientia 1992; 48: 301-304.
48. Gall EA. Benzene poisoning with bizarre extramedullary hematopoiesis. Arch Pathol 1938; 25: 315.
49. Rawson R, Parker FJr, Jackson HJr. Industrial solvents as possible etiologic agents in myeloid metaplasia. Science 1941; 93: 541.
50. Aksoy M. Malignancies due to occupational exposure to benzene. Haematologica 1980; 65: 370-373.
51. Port M, Hyman JB. Myeloid metaplasia as a result of chronic benzene intoxication. N Y State J Med 1965; 65: 2260-2262.
52. Uppenkamp M, Meusers P, Donhuijsen K, Brittinger G. Benzene-associated myelofibrosis at an early stage. Internist (Berl) 1990; 31: 769-772.
53. Bernardini P, Giannandrea F, Voso MT, Sica S. Myeloproliferative disorders due to the use of gasoline as a solvent: Report of three cases. Med Lav 2005; 96: 119-125.
54. Wakeford R. Radiation in the workplace-A review of studies of the risks of occupational exposure to ionising radiation. J Radiol Prot 2009; 29: A61-A79.
55. Caldwell GG, Kelley DB, Heath CWJr, Zack M. Polycythemia vera among participants of a nuclear weapons test. JAMA 1984; 252: 662-664.
56. Wolff SP, Stern G. Geographic associations between radon and cancer: Is domestic radon level a marker of socioeconomic status? J Radiol Prot 1991; 11: 225.